Status:
COMPLETED
Neoadjuvant Immunochemotherapy for Lung Cancer
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application...
Eligibility Criteria
Inclusion
- Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital;
- At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery;
- Malignancy was present and confirmed in the pathology before treatment and after surgery;
- The lung lesion was the primary lesion.
Exclusion
- No lung surgery was performed until 2022.11;
- No preoperative neoadjuvant therapy was performed or recorded;
- Neoadjuvant therapy did not include immune drugs;
- Previous history of malignancy (including surgery and adjuvant therapy);
- Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT06023797
Start Date
January 1 2017
End Date
July 1 2023
Last Update
September 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhencong Chen
Shanghai, Shanghai Municipality, China, 200032